Evaluation of pharmacokinetic interactions between the new SGLT2 inhibitor SHR3824 and valsartan in healthy Chinese volunteers
Y Huang, R Liu, Y Wang, G Liu, C Wang, X Chen… - Clinical Therapeutics, 2022 - Elsevier
Purpose Hypertension is often observed in patients with diabetes, and the progression of
diabetic nephropathy is closely related to blood pressure elevation. Thus, the effects of …
diabetic nephropathy is closely related to blood pressure elevation. Thus, the effects of …
Evaluation of Drug-Drug Interaction Between Henagliflozin and Hydrochlorothiazide in Healthy Chinese Volunteers
Q Chen, C Yu, Q Wu, R Song, Y Liu… - Drug Design …, 2024 - Taylor & Francis
Purpose Henagliflozin is an original, selective sodium-glucose cotransporter 2 (SGLT2)
inhibitor. Hydrochlorothiazide (HCTZ) is a common anti-hypertensive drug. This study aimed …
inhibitor. Hydrochlorothiazide (HCTZ) is a common anti-hypertensive drug. This study aimed …
No apparent pharmacokinetic interactions were found between henagliflozin: a novel sodium‐glucose co‐transporter 2 inhibitor and glimepiride in healthy Chinese …
L Que, K Huang, X Xiang, Y Ding… - Journal of Clinical …, 2022 - Wiley Online Library
What is known and objective Henagliflozin is a novel selective sodium‐glucose co‐
transporter 2 (SGLT2) inhibitor with similar inhibitory effect to ertugliflozin. Glimepiride is …
transporter 2 (SGLT2) inhibitor with similar inhibitory effect to ertugliflozin. Glimepiride is …
Pharmacokinetic and pharmacodynamic interactions between henagliflozin, a novel selective SGLT-2 inhibitor, and warfarin in healthy Chinese subjects
X He, G Liu, X Chen, Y Wang, R Liu, C Wang… - Clinical Therapeutics, 2023 - Elsevier
Purpose While controlling blood glucose, patients with diabetes and abnormal coagulation
should be treated with positive anticoagulation because the hypercoagulable state of their …
should be treated with positive anticoagulation because the hypercoagulable state of their …
Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus
X Yong, A Wen, X Liu, H Liu, YP Liu, N Li, T Hu… - Clinical drug …, 2016 - Springer
Abstract Background and Objective Henagliflozin, a selective inhibitor of the renal sodium
glucose cotransporter-2, was developed for type 2 diabetes mellitus (T2DM). This study …
glucose cotransporter-2, was developed for type 2 diabetes mellitus (T2DM). This study …
Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects …
Y Zhang, Y Liu, C Yu, Y Wang, Y Zhan, H Liu, J Zou… - Clinical Therapeutics, 2021 - Elsevier
Background Henagliflozin, a novel selective inhibitor of sodium–glucose cotransporter 2, is
under development as a treatment for type 2 diabetes mellitus. Purpose To evaluate the …
under development as a treatment for type 2 diabetes mellitus. Purpose To evaluate the …
Evaluation of drug–drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males
L Wang, C Wu, L Shen, H Liu, Y Chen, F Liu, Y Wang… - Xenobiotica, 2016 - Taylor & Francis
Henagliflozin is a novel sodium-glucose transporter 2 inhibitor and presents a
complementary therapy to metformin for patients with T2DM due to its insulin-independent …
complementary therapy to metformin for patients with T2DM due to its insulin-independent …
Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes
LG Huang, R Hu, HT Zou - Frontiers in Pharmacology, 2024 - frontiersin.org
Background More and more clinical guidelines have recommended use of sodium-glucose
cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, to prevent major adverse …
cotransporter-2 (SGLT2) inhibitors, also known as gliflozins, to prevent major adverse …
Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: implications for clinical practice
A Nicolucci, R Candido, D Cucinotta, G Graziano… - Advances in …, 2019 - Springer
Abstract Introduction Following the US Food and Drug Administration (FDA) guidance on the
evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of …
evaluation of novel agents for the treatment of type 2 diabetes mellitus (T2DM), a number of …
Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
JA Lovshin, RE Gilbert - Current Hypertension Reports, 2015 - Springer
By eliminating glucose in the urine, the sodium-glucose-linked cotransporter-2 (SGLT2)
inhibitors act as osmotic diuretics to lower blood pressure in addition to reducing plasma …
inhibitors act as osmotic diuretics to lower blood pressure in addition to reducing plasma …